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Abstract
The 22q13.3 deletion syndrome results from loss of terminal segments of varying sizes at 22qter.
Few genotype–phenotype correlations have been found but all patients have mental retardation
and severe delay, or absence of, expressive speech. We carried out clinical and molecular
characterization of 13 patients. Developmental delay and speech abnormalities were common to
all and comparable in frequency and severity to previously reported cases. Array-based
comparative genomic hybridization showed the deletions to vary from 95 kb to 8.5 Mb. We also
carried out high-resolution 244K array comparative genomic hybridization in 10 of 13 patients,
that defined the proximal and distal breakpoints of each deletion and helped determine the size,
extent, and gene content within the deletion. Two patients had a smaller 95 kb terminal deletion
with breakpoints within the SHANK3 gene while three other patients had a similar 5.5 Mb deletion
implying the recurrent nature of these deletions. The two largest deletions were found in patients
with ring chromosome 22. No correlation could be made with deletion size and phenotype
although complete/partial SHANK3 was deleted in all patients. There are very few reports on array
comparative genomic hybridization analysis on patients with the 22q13.3 deletion syndrome, and
we aim to accurately characterize these patients both clinically and at the molecular level, to pave
the way for further genotype–phenotype correlations.
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INTRODUCTION
The 22q13.3 deletion syndrome, also known as the Phelan–McDermid syndrome (OMIM #
606232), results from deletions of variable length involving the terminal long arm of
chromosome 22, either through a simple deletion or secondary to an unbalanced structural
rearrangement. To date, there have been over 100 cases reported in the literature; however,
the cryptic nature of this deletion in a significant fraction of cases often precludes a true
estimate of its prevalence making it likely to be under diagnosed. Deletion sizes from 100 kb
to greater than 9 Mb have been reported to give rise to this syndrome. Over the years,
common features have emerged which include developmental delay and delayed or absent
speech [Phelan et al., 2005]. While these seem to be the predominant features, autistic
features have also been found in nearly 50% of the patients [Cusmano-Ozog et al., 2007].
The clinical phenotype resulting from the submicroscopic terminal deletion has attracted
increased attention lately, due to developmental delay and significant speech impairment
typical of autism spectrum disorders observed in these children.
Efforts to identify the crucial gene(s) within this terminal segment led to the identification of
SHANK3 [SH3 and Ankyrin domain containing protein; formerly known as proline-rich
synapse associated protein 2 (PROSAP2)] as the critical gene within this interval. [Sheng et
al., 2000; Sala et al., 2001; Grant, 2003] Disruption of SHANK3 resulting in features of
22q13.3 syndrome was first reported in a child with a de novo balanced translocation t(12;
22)(q24.1; q13.3) [Bonaglia et al., 2001]. Subsequently, Anderlid et al. [2002] described the
disruption of SHANK3 resulting from a 100-kb deletion in a patient with the phenotype of
22q13.3 deletion syndrome. Wilson et al. [2003] published a report of 56 patients with
deletion sizes ranging from 130 kb to 9 Mb and showed that haploinsufficiency of SHANK3
was responsible for the major neurological symptoms of this syndrome. This was followed
by identification of a recurrent breakpoint within the SHANK3 gene in two unrelated patients
who had a similar SHANK3 disruption but exhibited different degrees of severity in their
phenotypes [Bonaglia et al., 2006]. Recently, point mutations resulting in haploinsufficiency
for SHANK3 have been identified in a small fraction of patients with idiopathic autism
[Durand et al., 2007; Moessner et al., 2007]. The smallest deletion reported involves the last
100 kb of chromosome 22q13.3, which includes three genes, SHANK3, ACR, and RABL2B.
Interestingly, a small fraction of patients with this syndrome harbored submicroscopic
rearrangements at 22qter that interrupted or led to a complete loss of these three genes only.
The largest terminal 22q deletions included more than 50 known genes.
Array-based comparative genomic hybridization (aCGH) helps to identify genomic
rearrangements at a resolution that is 5–10 times higher than that of routine chromosome
analysis by karyotyping. The diagnosis of the 22q13.3 deletion syndrome is based on
cytogenetic, molecular cytogenetic, and/or molecular demonstration of loss or disruption of
the 22q13.3 chromosomal region. Historically, most of the reported deletions in the 22q13.3
region were identified and characterized based on routine karyotyping as well as FISH using
the ARSA probe. To our knowledge, no further descriptions in the literature delineating the
breakpoints in these deletions have been made. We report the clinical and molecular data for
a series of 13 patients with deletion 22q13.3 with sizes varying from 95 kb to ~8.5 Mb.
High-resolution aCGH was carried out on 10 of these patients to delineate the size, extent,
gene content, and approximate boundaries of the deletions. A comparison of their clinical
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Clinical aCGH was performed on 8,500 samples that were referred to the Kleberg
Cytogenetic Laboratory, Houston, TX, USA, from September 2005 to September 2007.
From these, 21 cases were identified with varying sizes of deletion in the 22q13.3 region. A
total of 12 patients were included in this study, for which clinical information was available.
The 13th patient was also included who was diagnosed with a deletion using FISH.
Informed consent approved by the Institutional Review Board for Human Subject Research
at Baylor College of Medicine was obtained from their families.
DNA Samples
DNA was extracted from whole blood using the Puregene DNA extraction kit (Gentra,
Minneapolis, MN) according to the manufacturer’s instructions.
Chromosome and FISH Analyses
Chromosome and FISH analyses were performed on peripheral blood lymphocytes using
standard procedures. FISH analyses with the bacterial artificial chromosome (BAC) clones
were performed using standard procedures. Briefly, the BAC clone of interest was grown in
TB media with 20 μg/ml chloramphenicol. DNA was extracted from BAC clones
(Eppendorf Plasmid Mini Prep kit, Hamburg, Germany) and directly labeled with
SpectrumOrange™ dUTP by nick translation (Vysis, Downer Grove, IL) according to the
manufacturer’s instructions. Digital FISH images were captured by a Power Macintosh G3
System and MacProbe version 4.4 (Applied Imaging, San Jose, CA).
Microarray Procedures and Data Analysis
Four consecutive versions of arrays, each with a greater genetic coverage and higher
genome resolution, representing the chromosome microarray (CMA) evolution in our
clinical diagnostic laboratory, were applied during the study period. The CMA V5 BAC and
V6 BAC platforms were BAC arrays that have been reported in our previous studies [Shao
et al., 2008]. The CMA BAC V6 consisted of 1,475 BAC clones and interrogated over 150
genomic disorder loci, with expanded coverage in pericentromeric and subtelomeric regions,
and greater backbone coverage of the genome with inclusion of one clone per band at 650
cytogenetic banding resolutions. Blood samples from Patients 1, 5, 6, 9, 10, and 12 were run
on the CMA V5 BAC. The CMA BAC V6 platform was used for Patients 3, 4, and 7.
The CMA V6 OLIGO platform was designed based on the V6 BAC and consisted of 42,640
oligonucleotides, with the average of 20–40 oligonucleotides corresponding to each BAC
clone genomic locus [Ou et al., 2008]. Strict oligonucleotide selection criteria and removal
of repetitive sequences were employed to ensure high sensitivity and specificity with greater
dynamic range. The V6 OLIGO platform was designed by Baylor Medical Genetics
Laboratories and manufactured by Agilent Technologies, Inc. (Santa Clara, CA)
(http://www.bcm.edu/cma/table.htm). Samples from Patients 8 and 11 were run on V6 BAC.
The oligonucleotide array V7.2 OLIGO is a custom-designed array with about 105,000
oligonucleotides of 60 bp manufactured by Agilent Technologies, Inc. This array selected
the best performing oligos from the electronic library from Agilent as probes for virtually all
the known microdeletion or microduplication syndromes and the pericentromeric and
subtelomeric regions. In addition to these targeted regions, the entire genome (between
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disease regions) is covered with an average resolution of 30 kb while excluding repetitive
sequences through a combination of bioinformatics and computation. The V7.2 OLIGO
platform was used for Patient 2. Samples from Patients 3, 5, and 12 that were previously run
on older version arrays were re-analyzed on the V7.2 OLIGO.
The procedures for probe labeling and hybridization of the BAC arrays were reported
previously [Lu et al., 2007]. The procedures for DNA digestion, labeling, and hybridization
for the oligo arrays were performed according to the manufacturer’s instructions, with some
modifications [Ou et al., 2008]. The slides were scanned into image files using an Agilent
G2565 laser scanner. Microarray image files of oligoarrays were quantified using Agilent
Feature extraction software (v9.0), and text file outputs from the quantitation analysis were
imported into our in-house analysis package for copy number analysis, as described
previously [Ou et al., 2008].
244K aCGH Analysis
Whole Human Genome Oligo Microarray Kits 244K (Agilent Technologies, Inc.) were used
to analyze DNA from 10/13 patients to further delineate the identified genomic losses.
These included Patients 1 and 2 and 4–11. The procedures for DNA digestion, labeling, and
hybridization were performed according to the manufacturer’s instructions with some
modifications [Probst et al., 2007].
RESULTS
Molecular Analysis of Deletion
Molecular testing that detected the deletions in the patients was undertaken as follows:
a. Clinical aCGH was carried out in 12 of 13 patients. An example of Patient 3 is
shown in Figure 1A. Deletions were confirmed by partial karyotype (Patients 6 and
9) and by FISH in the remaining cases. All deletions were terminal as confirmed by
FISH utilizing subtelomeric probes. Patients 11 and 12 were noted to have ring
chromosome 22 by previous chromosomal analysis.
b. Higher resolution aCGH (244K) was carried out in 10 of 13 (77%) cases to
determine the sizes and extent of the deletion (Fig. 2). The smallest terminal
deletion was approximately 95 kb (Patients 1 and 2) and the largest deletion was
found in Patient 12 (8.55 Mb—data not shown). While Patients 1 and 2 had partial
deletions of SHANK3 with proximal breakpoints located within the gene, Patients
3–12 had complete deletions of SHANK3.
c. FISH testing in Patient 13 was initially performed to diagnose DiGeorge syndrome.
Interestingly, it showed a deletion of the ARSA probe, which was used as a control
probe for chromosome 22q, while the DiGeorge probe hybridized normally.
Further testing showed the deletion to involve SHANK3 using the n66c4 probe as
shown in Figure 1B. The location of the probes is shown in Figure 1C.
Clinical Profiling of Patients
The age of patients studied ranged from 3 to 19 years, and there were six males and seven
females. Developmental delay and significant speech delay and/or loss of speech were
common to all. Additional problems including history of feeding difficulties and recurrent
infections were less common (3/13, 23%) and found to coexist in Patients 8, 9, and 12 only.
Seizures were reported in only 4/13 (31%) individuals while Patient 4 had an abnormal EEG
with no clinically apparent seizure disorder. Table I outlines clinical features commonly
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seen in patients with the 22q13.3 deletion syndrome and their presence in the patients
described here.
Behavioral problems such as repetitive behaviors, impaired socialization, hyperactivity, and
self-stimulation were observed in 12 of 13 (92%) patients. Patient 12 was ventilator-
dependent and unable to move; hence his behavior could not be assessed. Five of 13 (38%)
patients had a formal neuro-developmental assessment. Patient 5 was diagnosed with
pervasive developmental delay with a developmental quotient (DQ) < 50. Patients 1 and 4
were diagnosed with autism using Autism Diagnostic Observation Schedule (ADOS),
Autism Diagnostic Interview (ADI), and Gilliam and Childhood Autism Rating Scale,
respectively. Patients 9 and 13 had formal testing but did not meet criteria for a diagnosis of
autism.
Common physical findings noted in the patients are listed in Table II (Fig. 3). Facial
dysmorphism was significant in at least four patients. Hypotonia was present in 4 of 13
(31%) patients. A comparison of the frequencies of the common clinical features observed
in patients with the 22q13.3 deletion syndrome as seen in this study and two previously
published reports is listed in Table III [Phelan et al., 2005; Cusmano-Ozog et al., 2007].
Brain imaging was performed in 9 of 13 patients as an initial test to evaluate the
developmental delay. Patients 3 and 5 showed mild thinning of the corpus callosum and
Patients 3, 8, and 10 had mildly delayed myelination. Brain MRI in Patient 1 showed brain
asymmetry with a larger size of left lateral ventricle compared to the right and loss of
normal left temporal horn morphology. The remainder (4 of 9 or 44%) had a normal brain
MRI. These results are similar to reports of brain imaging abnormalities in patients with the
22q13.3 deletion syndrome [Philippe et al., 2008].
DISCUSSION
Patients with the 22q13.3 deletion syndrome have a common phenotype characterized by
developmental delay, including gross motor delays and absent or delayed speech, hypotonia,
and craniofacial dysmorphic features. Clinical features of the patients in the present study
are similar to that of previous reports (Table III) except for the lower prevalence of
hypotonia in the present report. As established in previous reports, the present data also
suggest that developmental delay is an almost universal feature of the 22q13.3 deletion
syndrome. Behavioral problems such as impaired social skills, persistent mouthing, and
chewing of nonfood items, inattentiveness, and hyperactivity were found in 12 of 13 (92%)
patients. Sleep disturbances were also seen in 6 of 13 (46%) of the patients. A common
association of the 22q13.3 deletion syndrome with autism spectrum disorders has begun to
emerge, which is also supported in this cohort although only five patients received a formal
neuropsychological evaluation. The first reported association between autism and 22q13.3
deletion was published in a 14-year-old girl [Goizet et al., 2000].
Autism spectrum disorders are etiologically heterogeneous and are associated with a
recognizable cause in only 10% of patients, most commonly with fragile X syndrome,
tuberous sclerosis, and cytogenetically detectable chromosomal anomalies. Mutations in the
neuroligin genes (NLGN3 and NLGN4) on the X chromosome [Jamain et al., 2003] and
SHANK3 on chromosome 22q13 [Durand et al., 2007] are monogenic causes of autism
spectrum disorders. In one study of 400 unrelated subjects with autism spectrum disorder,
one de novo mutation and two gene deletions of the SHANK3 gene were discovered,
contributing 0.75% causality to this cohort [Moessner et al., 2007]. However, in another
recent study by Philippe et al. [2008] autism was suspected in seven of eight patients with
the 22q13.3 deletion syndrome. These patients did not fulfill DSM-IV criteria for autism.
Their relationship pattern, language development, and nature of repetitive behaviors were
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distinct from autism. In the patients described here, two of five (40%) patients who
underwent neuropsychological evaluations were diagnosed with autism. This is similar to
previous studies [Cusmano-Ozog et al., 2007].
Two of the patients reported here were found to have a ring chromosome 22 (Patients 11 and
12). r(22) is assumed to arise from breakage and subsequent fusion of both chromosome
arms to generate a ring chromosome with concomitant loss of terminal short and long arm
sequences. A review of 17 patients with r(22) showed that clinical features are similar in
patients with simple 22q13 deletion and r(22) patients when they are of similar ages and
similarly sized deletions [Luciani et al., 2003]. The features common in both conditions are
global developmental delay with severe speech delay, hypotonia, macrotia, epicanthal folds,
and small toenails. Patient 12 showed a degree of growth failure which is similar to
previously published reports of patients with r(22). These patients are known to exhibit
growth failure rather than accelerated growth as seen in 22q13.3 deletion syndrome [Hunter
et al., 1977; Jeffries et al., 2005].
Historically, FISH and chromosome G-banding have been commonly used to demonstrate
the deletions in this syndrome [Doheny et al., 1997]. Koolen et al. [2005] used aCGH on
nine patients with subtelomeric deletions of 22q and reported deletion sizes ranging from 3.3
to 8.4 Mb. At that time, they were unable to demonstrate a deletion–phenotype correlation.
They used a tiling resolution array with an average clone spacing of 100 kb. However,
minimal coverage across the most terminal segment of 22q precluded identification of
disruptions within or in the immediate vicinity of the SHANK3 gene, the haploinsufficiency
of which has been established to be associated with the neurological phenotype of patients
with the 22q13.3 deletion syndrome. It is clear that aCGH analysis offers higher resolution
compared to microscopic cytogenetics for molecular characterization of patients with this
phenotype.
All the patients described here had terminal deletion of the 22q13 region and in all of them,
either all or a part of the SHANK3 gene was found to be deleted. The deletion sizes ranged
from 95 kb (Patient 1) to 8.55 Mb (Patient 12). The two patients with the smallest deletion
had distinct phenotypes with Patient 1 showing more severe behavioral issues compared to
Patient 2. This is an example of the difficulty in making genotype–phenotype correlations in
patients with the 22q13.3 deletion syndrome. One hypothesis is that epigenetic factors may
play a role in the clinical features of this syndrome. Alternatively, sequence variations in
alleles on the nondeleted chromosome may have qualitative and/or quantitative effects on
their expression that is unmasked by deletion of their paired allele [Ching et al., 2005].
Three patients (Patients 7–9) had a similar sized ~5.5 Mb deletion. All three patients had
feeding problems while two of three had behavioral issues, seizures, and recurrent
infections. As more such patients are reported with exact deletion sizes and breakpoints, a
genotype–phenotype correlation could emerge, possibly delineating the role of other genes
contributing to the 22q13.3 phenotype. A recent report by Wilson et al. [2008] of two
patients with interstitial deletion of the 22q13 region with intact SHANK3 indicates that
haploinsufficiency for other 22q13 genes could also have major effects on cognitive and
language development. More studies are required to explore the interaction of these
proximal genes and their role in the neurological phenotype of this syndrome.
Approximately 90 genes are deleted in the largest sized deletion found in Patient 12,
whereas the smallest deletion segment contained the three genes, SHANK3, ACR, and
RABL2B (Fig. 1C). Some of the genes (besides SHANK3) responsible for clinically
significant disorders that are present in this interval include ARSA (metachromatic
leukodystrophy), TYMP (mitochondrial neuro-gastrointestinal encephalomyopathy), MLC1
(megalencephalic leukoencephalopathy with subcortical cysts), ALG12 (congenital disorders
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of glycosylation 1g), ATXN10 (cerebellar ataxia), UPK3A (renal adysplasia), and SULT4A1
(susceptibility to schizophrenia).
We hypothesize that there may be as yet uncharacterized genes in the vicinity of SHANK3,
SNP, or other variants within the regulatory sequences of SHANK3 itself, or modifier effects
of unlinked genes that qualitatively or quantitatively affect its expression. If the deletion
breakpoint is located within these regulatory genes, expression of SHANK3 could be altered
leading to a clinical phenotype. Point mutations in SHANK3, just as in the case of the
neuroligin genes, are rare in patients with autism. Micro-deletions and disruptions of
SHANK3, however, provide the most convincing evidence for a role in autism. It is possible
that similar microdeletions will identify additional genes that may contribute to the autism
phenotype [Jacquemont et al., 2006]. Such additional candidates may include genes that are
involved in the growth and development of the pre- and postsynaptic compartments.
In summary, this study illustrates the use of aCGH in delineating deletion breakpoints in the
22q13.3 deletion syndrome and highlights the utility of aCGH as a diagnostic tool for
analysis of patients with developmental delay, unexplained hypotonia, and autism spectrum
disorder with or without craniofacial dysmorphism. We anticipate that as more patients are
diagnosed with the 22q13.3 deletion syndrome using aCGH, a clearer picture of genotype–
phenotype correlation may emerge based on the variety of the deleted genes and the
differing sizes of the deletions.
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A: Representation of the clinical array CGH data in Patient 3 indicating a loss in copy
number (red circle). Below is shown the size and extent of deletions at 22q13 and the genes
involved in the region. B: FISH analysis using a cosmid clone (n66c4) as a target probe
labeled in red indicating a deletion involving the SHANK3 gene while RP11-316L10 is
labeled in green and serves as a control probe. C: Physical map of 22q13.3 region
representing SHANK3 and its neighboring genes ACR and RABL2B, the latter toward the
telomere. FISH probes (COSMIDS) used in the hybridizations are indicated in the green bar
below.
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Molecular data mapping the deletions in 10 patients on the 244K oligoarray which include
the estimated proximal breakpoint and the distal breakpoint and the size of the deletion.
Note: the deletion disrupts the SHANK3 gene in Patients 1 and 2.
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Facial features of six 22q13.3 deletion syndrome patients from this cohort. Photographs of
Patients 2, 4, 5, 7, 8, and 10 from left to right then bottom left to right, respectively. The
common features are listed in Table II. Individual features include: Patient 2: full cheeks;
Patient 4: mild ptosis and long eyelashes with thick, bushy eyebrows; Patient 5: upslanting
palpebral fissures with flat nasal bridge and long philtrum; Patient 7: bitemporal narrowing,
thick bushy eyebrows, and low set ears; Patient 8: flat nasal bridge; Patient 10: bitemporal
narrowing, upslanting palpebral fissures, and long eyelashes.
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TABLE III
Comparison of Frequencies of Common Clinical Features as Seen in the Patients in This Study and Previously
Published Reports [Phelan et al., 2001; Cusmano-Ozog et al., 2007]
Phenotype This study (n = 13) Cusmano-Ozog et al. (n = 107) Phelan et al. (n = 37)
Growth—normal to accelerated growth 11 95 35
Feeding difficulties 5 N/A N/A
Seizures 4 25 10
Autistic-like features and other behavioral issues 12 47 N/A
Hypotonia 4 92 36
Developmental delay 13 105 37
Absent/severely delayed speech 13 103 37
Epicanthal folds 4 32 15
Macrotia 9 58 24
Bulbous nose 8 N/A N/A
Large hands 6 35 25
Small nails 3 39 29
Am J Med Genet A. Author manuscript; available in PMC 2011 June 22.
